Taken together, these findings highlight the importance of refocusing efforts on prostate cancer screening and detection policies in England and the UK.

@natcan-news.bsky.social @alison-tree.bsky.social @prostatecanceruk.bsky.social

A higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods, suggesting that the risk of being diagnosed with metastatic prostate cancer is also linked to their socioeconomic background.

⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.

🚨 Regional annual rates were found to vary between 4 and 7 per 100 000 men, with the highest rates seen in Northern England; South Yorkshire and Bassetlaw; Humber, Coast and Vale; West Yorkshire and Harrogate; and the Peninsula. The lowest rates were seen in London and the South-East.

👉 Use varied across sMDTs from 20% to 54%, with greater variation in older patients

👉 Findings highlight underuse and the need for standardised care to address disparities

We hope you find this paper useful and please get in touch with any feedback npca@rcseng.ac.uk

The study explored variation in treatment intensification for mHSPC across England and found

👉 Only 39% received intensification with lower uptake in Black and deprived populations

👉 Intensification was given to 60% of men under 75 but dropped to 17% in those over 75

More details about the NPCA can be found here buff.ly/4kiLhxy and reports buff.ly/4klANxy and publications buff.ly/4kn1HF1. Enquiries can be made to npca@rcseng.ac.uk. Closing date 31st March 2025.

Please share widely @alison-tree.bsky.social @natcan-news.bsky.social @prostateukprofs.bsky.social

If the answer to these questions is yes, look no further! The National Prostate Cancer Audit (NPCA) is recruiting a Clinical Fellow to work with our large and detailed outcome-linked dataset to undertake research for patient benefit. Apply here www.jobs.ac.uk/job/DMB374/c...

The next quarterly report will be published in April 2025, to align with the reporting schedule for all other NATCAN audits, and will mark the NPCA transition to using an RShiny dashboard. Examples of the NATCAN dashboards for other tumour types can be found here https://buff.ly/4gIQLyu